South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical trials. The company said it is using organoids – small ...

Triangle firm slaps feds with lawsuit over delayed product launch Morrisville firm stunned by FDA setback, vows 'quick action ...

The fresh funds provided by the European Innovation Council will help the Cambridge-based company overcome technical barriers ...